Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening – The VICTORION-PLAQUE primary prevention trial

By afschroeder • August 7, 2025

Revaiah PC, Serruys PW, Onuma Y, Andreini D, Budoff MJ, Sharif F, Chernofsky A, Vikarunnessa S, Wiethoff AJ, Yates D, Achouba A. Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening - The VICTORION-PLAQUE primary prevention trial. Am Heart J. 2025 Aug 4:S0002-8703(25)00291-1. doi: 10.1016/j.ahj.2025.08.001. Epub ahead of print. PMID: 40769373.

Tags: Cardiology/Epi, CCTA derived Fractional Flow Reserve (FFR(CT)), coronary computed tomography angiography (CCTA), CT-adapted Leaman score, Harbor UCLA, Inclisiran, Low density Lipoprotein Cholesterol (LDL-C), non-obstructive coronary artery disease (NOCAD), Publications, total atheroma volume (TAV)

Reperfusion Strategies for Acute Pulmonary Embolism: Design and Rationale of RECONNECT-PE – a Living Systematic Review and Meta-analysis

Farmakis IT, Binder H, Chopard R, Christodoulou KC, Evrenoglou T, Fengler K, Giri J, Hobohm L, Jaber WA, Klok FA, Kocka V, Kroupa J, Kucher[...]

MoCo + ROVir: Synergy Between Respiratory Motion Compensation and Cardiac Receive Region Focusing for Cardiac MRI

Hu Z, Lee HL, Cao T, Yoshida T, Ma L, Finn JP, Nguyen KL, Christodoulou AG. MoCo + ROVir: Synergy Between Respiratory Motion Compensation and Cardiac Receive[...]

The Cost-Effectiveness Evolution of Cardiovascular Care

Fonarow GC, Navar AM, Yancy CW. The Cost-Effectiveness Evolution of Cardiovascular Care. JAMA Cardiol. 2026 Feb 4. doi: 10.1001/jamacardio.2025.5240. Epub ahead of print. PMID: 41637084.